tbuckley/cabot-search huggingface dataset:
N-Oxidation of Certain Aromatic Amines, Acetamides, and Nitro Compounds by Monkeys and Dogs2
Authors: Jack L. Radomski, Gaylord M. Conzelman, Alberto A. Rey, Earl Brill
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article N-Oxidation of Certain Aromatic Amines, Acetamides, and Nitro Compounds by Monkeys and Dogs Get access Jack L. Radomski, Jack L. Radomski Department of Pharmacology, University of Miami, School of Medicine, Miami, Florida 33152; Department of Physiological Sciences, School of Veterinary Medicine, University of California, Davis, California 95616 Search for other works by this author on: Oxford Academic PubMed Google Scholar Gaylord M. Conzelman, Jr., Gaylord M. Conzelman, Jr. Department of Pharmacology, University of Miami, School of Medicine, Miami, Florida 33152; Department of Physiological Sciences, School of Veterinary Medicine, University of California, Davis, California 95616 Search for other works by this author on: Oxford Academic PubMed Google Scholar Alberto A. Rey, Alberto A. Rey Department of Pharmacology, University of Miami, School of Medicine, Miami, Florida 33152; Department of Physiological Sciences, School of Veterinary Medicine, University of California, Davis, California 95616 Search for other works by this author on: Oxford Academic PubMed Google Scholar Earl Brill Earl Brill Department of Pharmacology, University of Miami, School of Medicine, Miami, Florida 33152; Department of Physiological Sciences, School of Veterinary Medicine, University of California, Davis, California 95616 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 4, April 1973, Pages 989–995, https://doi.org/10.1093/jnci/50.4.989 Published: 01 April 1973 Article history Received: 01 September 1972 Accepted: 31 October 1972 Published: 01 April 1973
Evidence for an Anticomplementary Factor Associated With Human Bone Marrow Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: A P Gee, K M Bruce, T D Morris, M D Boyle
Journal: JNCI Journal of the National Cancer Institute (1985)

Complement (C)-mediated lysis of antibody-sensitized sheep erythrocytes was inhibited by the addition of human bone marrow cells. The anticomplementary activity could be attributed to a soluble factor that was released from the bone marrow cells. This factor inhibited at an early stage in the C-cascade and showed the characteristics of a factor that accelerates decay of C2. The release of such a factor by bone marrow cells would present an obstacle to the use of antibody and C to purge tumor cells from bone marrow that is to be used for autologous transplantation.
Abstract 17534: Predictors of Progression of Aortic Valve Stenosis in Medically Treated Patients With Low-Flow Significant Aortic Stenosis
Authors: Glenn K Lee, Valencia Lim, Ivandito Kuntjoro, Edgar L Tay, Tiong Cheng Yeo, Kian Keong Poh
Journal: Circulation (2013)

Background and Aims:  The progression of aortic valve stenosis (AS) in patients with the paradoxical low-flow state despite preserved left ventricular ejection fraction (LVEF) has not been previously studied. We aim to determine its predictors in medically treated patients.   Methods:  We studied 153 consecutive patients with low-flow (stroke volume index, SVI  180 days apart. Besides conventional echocardiography, valvuloarterial impedance (Zva), a measure of global left ventricular afterload, was calculated. There were 49 patients (32%) with a significant (>20%) decrease in AVAI (Group A). We compare their baseline clinical and echocardiographic parameters to the group without deterioration (Group B).   Results:  The mean time interval between paired studies is 909±834 days. Over this period, the mean AVAI decreased from 0.62 to 0.45 cm2.m-2 (p   Conclusion:  Low-flow AS patients with preserved LVEF, smaller AVAI and higher prevalence of diabetes tended to progress more rapidly. They may benefit from more intensive follow-up as well as optimal timing of valve replacement.
Omission of day 2 of 5ht3 antagonists: A new and cost saving strategy for improving delayed chemotherapy-induced nausea and vomiting control
Authors: P. P. Lajolo, B. d. Camargo, A. D. Glgio
Journal: Journal of Clinical Oncology (2008)

20538 Background: Nausea and vomiting are two of the most important symptoms observed in cancer patients. In a previous study we showed that delayed chemotherapy-induced nausea and vomiting (CINV) control could be potentially improved by skipping the administration of a 5HT3 antagonist on day 2. We report here a phase III randomized trial confirming our previous findings. Methods: Phase III randomized placebo-controlled trial was conducted in which all patients received (IV) ondansetron 16 mg, dexamethasone 20 mg and ranitidine 50 mg before highly/moderately emetogenic chemotherapy on day 1, and then randomized to one of two groups: Group A received metoclopramide 10 mg PO q8 hours, granisetron 0.5 mg PO QD, dexamethasone 8 mg QD and ranitidine 150 mg q12 for two days starting on day 2, and metoclopramide alone was continued on the same schedule on day 4. Group B received placebo on day 2 and the same treatment schedule as group 1 from day 3 to 5. Results: 73 patients were enrolled. The two groups were similar regarding clinical characteristics, despite the better control during the acute phase of CINV in group A (p=0.04). Complete control of nausea/vomiting (CCNV) from day 1 to 5 was similar in both groups. (30 % vs. 32%; p=0.5). Selecting only patients who achieved acute CCNV, we observed that group B had a better control of delayed CINV (85% vs 50%, p=0.02). FLIE scores did not differ significantly between groups A and B. Conclusions: Delayed CINV control can be improved just by skipping day 2 of 5HT-3 antiemetic medication. This effect may be due to tachyphylaxis that may develop in patients who take these medications continuously. Future studies should compare this simple and inexpensive strategy with the use of a more expensive NK-1 antagonist or second generation 5HT-3 antagonists. No significant financial relationships to disclose.
Omalizumab Decreases Rates of Cold Symptoms in Inner-City Children with Allergic Asthma
Authors: Ann T. Esquivel, William W. Busse, Agustin Calatroni, Peter J. Gergen, Kristine Grindle, Rebecca S. Gruchalla, Meyer Kattan, Carolyn Kercsmar, Gurjit K. Khurana Hershey, Haejin Kim, Petra Lebeau, Andrew H. Liu, Stanley J. Szefler, Stephen J. Teach, Jacqueline A. Pongracic, Joseph B. West, Jeremy Wildfire, James E. Gern
Journal: Journal of Allergy and Clinical Immunology (2016)
EXTRA Trial-Evaluation of capecitabine treatment with radiotherapy (RT) in anal cancer: Preliminary results on toxicity and outcome
Authors: R. Glynne-Jones, H. Meadows, S. Wan
Journal: Journal of Clinical Oncology (2006)

14085 Background: Phase III trials have shown RT + 5-Fluorouracil (5-FU) + mitomycinC (MMC) as the standard treatment for patients with epidermoid anal carcinoma. The objective of this trial is to determine if capecitabine in combination with MMC has a similar outcome in terms of complete response (CR) rate and toxicity to a 5-day infusion of 5-FU. Capecitabine is a rational alternative to 5-FU as these cancers express high levels of thymidine phosphoralase. Methods: Main eligibility criteria are histologically proven anal carcinoma (epidermoid, squamous, basaloid), fit to receive capecitabine and MMC and ineligible for the ongoing phase III UK trial, ACT II. Exclusion criteria include complete local excision, prior chemoradiation, uncontrolled cardiovascular disease and known HIV+ve. All patients receive: 50.4Gy in 28F(RT) and capecitabine 1650mg/m2/day on each RT treatment day (M-F) over 6 weeks. In addition patients receive MMC 12mg/m 2 , day 1 only. Assessment of response is by CT scan at 4 wks post chemoradiation. Results: To date 18/30 patients have been registered. Pre-treatment characteristics are: median age 59 yrs (44–85); 7 male, 11 female; 13 Canal, 5 Margin; 5T1, 4T2, 6T3, 2T4, 1Tx; 4N+ve, 13N-ve, 1Nx. Data on 14 evaluable pts are presented here. RT compliance: 12 pts completed planned treatment, treatment was interrupted in 2 cases (chest pain 1; machine breakdown 1). Chemotherapy compliance: 10 pts completed protocol treatment, in 3 pts chemotherapy was affected due to toxicity (1 dose reduced, 2 stopped early 1 due to chest pain and 1 due to grade 3 skin and diarrhoea). One patient decided to stop treatment. Grade 3 toxicity was reported in 2 pts during treatment: dyspnoea 1, diarrhoea 1. Four weeks post chemoradition, 10 had CR, 3 had partial response and 1 pt was not assessable. Thirteen pts are alive and disease free at a median follow-up of 6 months (range 1 -13). One pt has relapsed in an inguinal node 9 months after the end of treatment following a previous CR. Conclusions: This early information suggests that this regimen can be given without interruption and with acceptable toxicity. The early response data is encouraging and the trial aims to reach target accrual by Summer 2006. Educational grant provided by Roche pharmaceuticals. [Table: see text]
Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F)
Authors: E Holler, HJ Kolb, J Mittermuller, M Kaul, G Ledderose, T Duell, B Seeber, M Schleuning, R Hintermeier-Knabe, B Ertl
Journal: Blood (1995)
Trace Elements in Human Nutrition
Authors: M H Golden
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II of oxaliplatin, 5 fluorouracil and folinic acid (modification of folfox regimen) in patients with advanced gastric cancer (CGA): Preliminary results
Authors: G. Calderillo Ruiz, C. Cano Blanco, J. M. Ruiz Molina, H. Lopez Basave, G. Guerrero Ceron, E. Juarez Solis
Journal: Journal of Clinical Oncology (2005)

4269 Background: Gastric cancer is the second cause of death per cancer in Mexico, with more 5000 deaths/year. There is no standard chemotherapy in CGA but Louvet (J Clin Oncol 2002,20:4543) and Salah-Eddin (J Clin Oncol 2004,22:658) demostrated the efficacy (45% and 43% overall response rate) and acceptable safety of the oxaliplatin/5FU/FA combination. The pupose: to evaluate the toxicity and efficacy of oxaliplatin days 1,15 with 5-fluorouracil and folinic acid days 1,8,15 each 4 weeks. Methods: Ten patients with unresectable CGA and no prior chemotheray were into the study. Patient characteristics were: gender (male 7, female 3); median age 54 years (34–71); median performance status ECOG= 0. Two patients had locally advanced, inoperable disease while 8 had distant metastases (peritoneum 4, liver 2, lung and liver 1, ovary and peritoneum 1). All patients were evaluable for toxicity and response. Outpatient treatment consisted of oxaliplatin 80mg/m2 day 1 and 15, 5FU 500 mg/m2 iv bolus and folinic acid 20 mg/m2 iv bolus days 1,8 and 15, every 4 weeks. Results: A total of 47 courses of chemotherapy were administered. The response: overall response 6 pts (1 complete and 5 partial), stable disease 1 pt and progression 3 pts. Two patients underwent complete surgical resection (1 pt with confirmed complete pathological response). Median survival is 9.5 months. Grade 3/4 toxicities were: neutropenia in 1 pt, peripheral neuropathy in 1 case and venous thrombosis in 1 pt. No toxic deaths were seen. Conclusions: This oxaliplatin/5FU/FA regimen with low dose of fluorouracil and folinc acid in bolus, shows good efficacy and minimum toxicity en CGA patients No significant financial relationships to disclose.
Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
Authors: T. Ciuleanu, V. Nikolic, E. Shmueli, D. Vrbanec, S. Plate, Z. M. Krmpotic, M. Dank, G. Purkalne, T. Brodowicz, C. Zielinski
Journal: Journal of Clinical Oncology (2011)

3580 Background: FOLFOX4 + q1w cetuximab is a standard 1st-line regimen in KRAS wt mCRC. This trial evaluated FOLFOX4 + q1w cetuximab (Arm A) and FOLFOX4 + q2w cetuximab (Arm B) as 1st-line therapy in KRAS wt mCRC. Methods: Pts with KRAS wt mCRC were randomized to q1w cetuximab (400 mg/m2initial dose then 250 mg/m2/wk) or q2w cetuximab (500 mg/m2 every 2 wks). Both arms received FOLFOX4 (folinic acid 200 mg/m2, then 5-FU 400 mg/m2 bolus, then 5-FU 600 mg/m2 over 22 h on days 1+2, plus oxaliplatin 85 mg/m2 on day 1 q2w). Primary endpoint was objective response rate (ORR). Secondary efficacy endpoints were disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Results: 152 pts with KRAS wt tumors (22 centers in 12 countries) were randomized to arm A (n=75) and arm B (n=77). Baseline characteristics were well balanced. Median follow up for PFS analysis was 16.5 months. Overall ORR (55% vs 59%) and PFS (9.5 mo vs 9.3 mo) were similar in patients with EGFR detected and nondetectable tumors. OS data are not yet mature. Based on current data most common (≥10% in either arm) G3/4 treatment emergent adverse events were comparable in FOLFOX + q1w cetuximab and FOLFOX + q2w cetuximab: neutropenia/neutrophil decrease (32% vs 34%), rash (15% vs 16%), diarrhea (7% vs 10%). G3/4 composite adverse events categories specific to cetuximab or FOLFOX showed no difference between treatment arms: infusion-related reactions (2.7% vs 2.6%), skin reactions (24% vs 26%), neurotoxicities (0% vs 1.3%). Conclusions: These data suggest that in terms of ORR, DCR, PFS and safety, cetuximab q2w is a convenient alternative to the standard q1w regimen when combined with FOLFOX4. Determination of EGFR expression status does not help to identify patients more likely to benefit from treatment. Arm A (n=75) Arm B (n=77) ORR % (95% CI) 51 (39,62) 62 (51,73) Odds ratio (95% CI) 1.56 (0.82, 2.96) P value* 0.18 DCR % (95% CI) 87 (77-93) 86 (76-93) Odds ratio (95% CI) 0.90 (0.35, 2.28) P value* 0.83 PFS median, months (95% CI) 9.5 (7.6-11.2) 9.2 (7.8-10.0) Hazard ratio 0.98 (0.66, 1.45) P value* 0.91 *Two-sided CMH or log-rank test stratified for “number of organs involved” and “prior therapy.”
Contribution of Body Weight and Growth to Risk of Anterior Pituitary Gland Tumors of the Rat&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Morris H. Ross, Edward D. Lustbader, Gerrit Bras
Journal: JNCI Journal of the National Cancer Institute (1983)

The dietary and growth histories of noninbred male Charles River COBS rats permitted freedom of dietary choice throughout life were analyzed to determine the conditions associated with the spontaneous occurrence of anterior pituitary gland tumors (PT). The animals were allowed to regulate their protein intake apart from energy intake. Multivariable models were derived distinguishing rats that develop PT from those remaining free of tumors throughout life. Conventional fixed diet studies suggested that the quantity and quality of the diet consumed would be the best explanatory variables. However, body weight-related variables were found to be more important. The interacting, time-related conditions conductive to a high probability of PT occurrence included an unusually high growth rate associated with a high level of conversion of the food consumed into body mass during early life and a high intake of protein relative to body weight during early adult life. The accuracy in identifying rats with PT was even greater if mature body weight was included as an explanatory variable.
Hazardous drugs in developing countries [editorial]
Authors: Menkes Db
Journal: BMJ (1997)

This editorial points out the variety of problems with pharmaceutical drugs and hazardous drugs in developing countries: availability and promotion of unsafe drugs counterfeit drugs high costs health impacts inadequate control and lack of administrative machinery to police the infractions.  The medical community has a responsibility to influence industrial and government drug and medicine policies.  Unrestricted market forces do not assure the promotion of public health interests.  The priority in developing countries is for rational use of cost-effective pharmaceuticals and enforceable agreements to control promotion of nonessential and hazardous agents.  Inappropriate pharmaceuticals can result in fatal poisoning the spread of antibiotic resistant infections and other problems related to the mismanagement of diarrhea in children.  Unrestricted use of pharmaceuticals particularly affects women and children.  Research indicates that a countrys capacity to restrict dangerous drugs is mainly dependent on its wealth or its administrative machinery to monitor dangerous drugs.  There are unscrupulous business people who distribute fakes of acceptable drugs.  Counterfeit drugs can be manufactured locally or imported from Western countries.  In 1993 drug exports from the United States to developing countries were found to have  labeling deficiencies.  Locally produced drugs may also have more severe labeling errors.  Labeling may exaggerate indications minimize adverse effects or misspecify use.  Drugs that were banned or restricted in the country of manufacture may be promoted in developing countries.  Transnationals despite international resolutions continue to promote drugs in an irresponsible way exploit limited national restrictions on imports and behave unethically.  The Health Action International and the Medical Lobby for Appropriate Marketing monitor and publicize improper marketing and use of drugs.
Early placenta insuline-like peptide (pro-EPIL): A novel biomarker in advanced and metastatic non-small cell lung cancer (NSCLC) patients treated by chemotherapy
Authors: J. Ayllon, S. Oudard, E. Banu, J. L. Janneau, D. Helley, S. Richon, A. Banu, E. Levy, J. Medioni, D. Bellet
Journal: Journal of Clinical Oncology (2006)

20069 Background: Some studies suggest a causal relationship between the early placenta insuline-like peptide encoded by the insulin-like 4 gene and cancer invasiveness. Methods: Serum concentrations of pro-EPIL were measured by ELISA using a novel two-site “sandwitch” assay, based on two monoclonal antibodies (mAb) raised against synthetic peptides analogous to two distinct regions of the pro-Epil polypeptide: mAb EPIL15, and biotinylated mAb EPIL02, used as the labelled indicator. The first mAb EPIL15 was purified and bound to a solid phase. Pro-EPIL was allowed to bind, and unbound proteins were removed by washing. The sensitivity limit of the assay was 3 ng/mL of synthetic peptide, and detection was linear over a range of at 3 pg to 200 ng of the synthetic peptide. As primary endpoint, we studied the Pro-EPIL distribution according to some clinico-biological prognostic factors. Results: Between July 2001 and April 2005, nineteen chemonaive NSCLC pts were treated by chemotherapy in our center and serum determinations of pro-EPIL were performed. Ten pts (63%) overexpressed pro-EPIL before start of chemotherapy with a median value of 1.06 ng/mL (range 0.01–6.75). Median age was 60 years (range 38–80), more than 90% of pts were men with an advanced or metastatic disease. Forty-two percent of pts had a large cell carcinoma subtype, with 25% of adenocarcinoma and 25% of epidermoid type. Immunologic evaluations were performed with a median value of the CD3+ lymphocites of 1290/mm 3 (range 610–2138). Significant correlations were observed between age, serum alcaline phosphatase and CD3+ number. A border-line positive correlation was observed between pro-EPIL and CD3+ levels (P = 0.09, R 2 = 0.5). Median OS for entire cohort was 7.5 months (95% CI, 5.5–9.4), with 67% deaths. Because our sample size was very low, no survival analysis were performed according to the baseline pro-EPIL value and other prognostic factors. A bootstrapping procedure is planned on our data. Conclusions: This results showed that pro-EPIL was overexpressed in the majority of advanced NSCLC pts. Interactions between this biomarker and immune system are possible. Furthemore, pro-EPIL as a therapeutic target might be tested in prospective studies. No significant financial relationships to disclose.
The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy.
Authors: I H Krakoff
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.2.432 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8113852 The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy. I H KrakoffxI H KrakoffSearch for articles by this author Show More Division of Medicine, University of Texas M. D. Anderson Cancer Center, Houston 77030. https://doi.org/10.1200/JCO.1994.12.2.432 First Page PDF © 1994 by American Society of Clinical Oncology
Nerve Growth Factor and Nerve Growth-Stimulating Activity in Sera From Normal and Neuroblastoma Patients&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Bill, Alexander H., Seibert, Ellen S., Beckwith, J. Bruce, Hartmann, John R.
Journal: JNCI Journal of the National Cancer Institute (1969)

Journal Article Nerve Growth Factor and Nerve Growth-Stimulating Activity in Sera From Normal and Neuroblastoma Patients Get access Alexander H. Bill, M.D., Alexander H. Bill, M.D. Children's Orthopedic Hospital and Medical Center, Seattle Washington 98105 Search for other works by this author on: Oxford Academic PubMed Google Scholar Ellen S. Seibert, B.A., Ellen S. Seibert, B.A. Children's Orthopedic Hospital and Medical Center, Seattle Washington 98105 Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Bruce Beckwith, M.D., J. Bruce Beckwith, M.D. Children's Orthopedic Hospital and Medical Center, Seattle Washington 98105 Search for other works by this author on: Oxford Academic PubMed Google Scholar John R. Hartmann, M.D. John R. Hartmann, M.D. Children's Orthopedic Hospital and Medical Center, Seattle Washington 98105 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 43, Issue 6, December 1969, Pages 1221–1230, https://doi.org/10.1093/jnci/43.6.1221 Published: 01 December 1969 Article history Received: 01 April 1969 Accepted: 03 September 1969 Published: 01 December 1969